(154 days)
The Histofreezer® Wart Removal System is indicated for over-the-counter treatment of common warts and plantar warts.
The Histofreezer® Wart Removal System is a cryosurgical system for the treatment of warts. It consists of: A canister filled with a liguid mixture of the compressed gases dimethyl ether, propane 0 and isobutane o Custom applicators O An illustrated description of how to use the product
The provided text does not contain information about specific acceptance criteria or a study designed to prove the device meets such criteria. The document is a 510(k) summary for the Histofreezer® Wart Removal System, which focuses on demonstrating substantial equivalence to a predicate device rather than conducting a new performance study with explicit acceptance criteria.
The main points of the document are:
- Device Name: Histofreezer® Wart Removal System
- Intended Use: Over-the-counter treatment of common warts and plantar warts.
- Basis for Equivalence: Substantial equivalence to the prescription Histofreezer® device (K911420, K924114, K971392) for the same indications, and commercial predicate devices (Wartner Wart Removal System, Compound W Gel, Clear Away Liquid, Clear Away One Step for Kids, Rite Aid Wart Liquid, Suave Hairspray) regarding labeling, safety, and intended use.
- Technological Characteristics: Both the proposed device and the predicate device are portable cryosurgical systems using a canister with cryogen and an applicator.
- Conclusion: The device is deemed safe, effective, and substantially equivalent to the predicate devices.
Therefore, I cannot provide a table of acceptance criteria or details of a study proving the device meets them from the given text.
To address the specific points of your request, based only on the provided text:
- A table of acceptance criteria and the reported device performance: Not available in the provided text. The document asserts substantial equivalence based on intended use, technological characteristics, and safety/labeling similarities rather than presenting a performance study with defined criteria.
- Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective): Not applicable. No test set or performance data is presented.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience): Not applicable. No test set or ground truth establishment process is described.
- Adjudication method (e.g., 2+1, 3+1, none) for the test set: Not applicable. No test set or adjudication is mentioned.
- If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This device is a physical cryosurgical system, not an AI-assisted diagnostic tool.
- If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: Not applicable. This refers to a physical device, not an algorithm.
- The type of ground truth used (expert concensus, pathology, outcomes data, etc): Not applicable. No ground truth is described for a performance study.
- The sample size for the training set: Not applicable. No training set is mentioned as this is not an AI/algorithm-based device.
- How the ground truth for the training set was established: Not applicable. No training set or ground truth for it is described.
{0}------------------------------------------------
PREMARKET NOTIFICATION 510(k) SUMMARY (As Required By 21 CFR 807.92)
MAR 2 0 2003
807.92 (a):
| 1. | Submitter's Name: | OraSure Technologies, Inc. |
|---|---|---|
| Address: | 150 Webster St., Bethlehem, PA 18015 | |
| Telephone Number: | (610) 882-1820 | |
| Contact Person: | R. Sam Niedbala, Ph.D., BCFE | |
| Date Prepared: | October 15, 2002 |
-
- Device Name: Histofreezer® Wart Removal System or other proprietary name Proprietary Name: Usual Name: OTC wart removal system Classification Name: Cryosurgical unit, accessories
- Device to Which Substantial Equivalence Is Claimed: Histofreezer® Device, by OraSure Technologies, Inc. (Primary Predicate) - K911420, K924114, K971392 Wartner Wart Removal System, by Wartner Medical Products (OTC claim) - K011708 Compound W Gel, by Medtech (labeling only) Clear Away Liquid, by Schering-Plough HealthCare Products, Inc. (labeling only) Clear Away One Step for Kids, by Schering-Plough HealthCare Products, Inc. (labeling only) Rite Aid Wart Liquid, by Rite Aid Corporation (labeling only) Suave Hairspray, by Helene Curtis (flammability label only)
-
Description of Device: 4.
The Histofreezer® Wart Removal System is a cryosurgical system for the treatment of warts. It consists of: -
A canister filled with a liguid mixture of the compressed gases dimethyl ether, propane 0 and isobutane
-
o Custom applicators
-
O An illustrated description of how to use the product
-
న. Intended Use Statement:
The Histofreezer® Wart Removal System is indicated for over-the-counter treatment of common warts and plantar warts.
- Comparison of Technological Characteristics: 6.
The Histofreezer® Wart Removal System for over-the-counter treatment of common and plantar warts is substantially equivalent to the Histofreezer® device for the same indications (for prescription use). Both devices are portable cryosurgical systems comprised of a canister containing cryogen and an applicator that is saturated with cryogen and then applied to the wart to be treated. The Histofreezer® Wart Removal System, however, is intended for OTC treatment of common warts and plantar warts.
{1}------------------------------------------------
The labeling of the Histofreezer® Wart Removal System has been developed to ensure the consumer has adequate directions for use and for safety. Histofreezer® labeling has also been developed to provide adequate information for the consumer to make a self diagnosis and to ensure that they contact their doctor if in any doubt, if stinging or aching persists after treatment, or if the wart does not improve after four treatments.
The safety and warning statements for the OTC predicate device (Wartner Wart Removal System) and for all of the labeling predicate devices is essentially similar.
7. Conclusion:
Based on the information presented above, it is concluded that the proposed Histofreezer® Wart Removal System is safe and effective for its intended use and is substantially equivalent to the primary predicate device. It is also substantially equivalent in intended use, safety, and labeling to the labeling predicate devices.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol of three wavy lines, which are meant to represent the human services aspect of the department.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
APR 2 5 2003
R. Sam Niedbala, PH.D., BCFE Orasure Technologies, Inc. 150 Webster Street Bethlehem, Pennsylvania 18015-1389
Re: K023487
Trade/Device Name: Histofreezer® Wart Removal System Regulation Number: 21 CFR 878.4350 Regulation Name: Cryosurgical unit and accessories Regulatory Class: II Product Code: GEH Dated: February 5, 2003 Received: February 19, 2003
Dear Dr. Neidbala:
This letter corrects our substantially equivalent letter of March 20, 2003, regarding the intended use of the device mentioned above. The intended use for the device was over-the-counter, however, the indications for use form indicated prescription use.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent [(for the indications for use stated in the enclosure)] to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2 - R. Sam Niedbala, PH.D., BCFE
This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at their toll free number (800) 638-2041 or at (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Muriam C. Provost
Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
STATEMENT OF INDICATIONS FOR USE
510(k) Number (if known): _ K023487
Device Name: Histofreezer® Wart Removal System or other proprietary name
Indications For Use: The Histofreezer® Wart Removal System is indicated for over-the-counter treatment of common and plantar warts.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109) OR
Over-The-Counter Use
c:\fda\indica.doc
Miriam C. Provost
(Division Sign-Off) Division of General, Restorative and Neurological Devices
510(k) Number Kc23487
§ 878.4350 Cryosurgical unit and accessories.
(a)
Identification —(1)Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold.(2)
Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold.(3)
Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.(b)
Classification. Class II.